Results 211 to 220 of about 414,323 (331)
T lymphocyte-mediated suppression of myeloma function in vitro. II. Evidence for regulation of hapten-binding myelomas by syngeneic hapten-specific cytolytic T lymphocytes. [PDF]
, 1980 Abul K. Abbas, S Ratnofsky, S J Burakoff
openalex +1 more source
Journal of the American Society of Nephrology, 2006 Stephen M, Korbet, Melvin M, Schwartz
openaire +2 more sources
Small Science, EarlyView.This review highlights recent advances in nanomedicine that enhance chimeric antigen receptor (CAR) T cell therapy against solid tumors. It discusses key barriers to CAR T cell efficacy and outlines nanotechnology‐based strategies to improve tumor targeting, remodel the immunosuppressive microenvironment, and integrate nanomaterials into CAR T cell ...
Stephen O’Rourke +3 more
wiley +1 more source
Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells. [PDF]
Hematol RepOkabe S +6 more
europepmc +1 more source
Multiple myeloma with intramedullary masses of M-component [PDF]
, 1975 GM Bernier +3 more
openalex +1 more source
Solamargine induces acute myeloid leukemia differentiation through TLR8 activation
VIEW, EarlyView.SM, a steroidal alkaloid from Solanum nigrum L. has shown anticancer effect on various kinds of human cancer cells, yet its effect on leukemia cells remains unclear. This study examines antileukemic activities of SM in AML cells. Results indicate SM inhibits growth and promotes apoptosis of AML cells.
Qiaoyan Han +11 more
wiley +1 more source
Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–4753. [PDF]
, 2012 openalex +1 more source